Patents by Inventor Fong Wang-Clow

Fong Wang-Clow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION TREATMENT WITH t-PA VARIANT AND LOW MOLECULAR WEIGHT HEPARIN
    Publication number: 20100196348
    Abstract: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
    Type: Application
    Filed: February 5, 2010
    Publication date: August 5, 2010
    Inventors: Paul ARMSTRONG, Hal BARRON, Silvano BERIOLI, Frederique BIGONZI, Erich BLUHMKI, Richard CHIN, Christopher GRANGER, Frans VAN DE WERF, Fong WANG-CLOW
  • Combination Treatment with t-PA Variant and Low Molecular Weight Heparin
    Publication number: 20090004177
    Abstract: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
    Type: Application
    Filed: August 4, 2008
    Publication date: January 1, 2009
    Inventors: Paul Armstrong, Hal Barron, Silvano Berioli, Frederique Bigonzi, Erich Bluhmki, Richard Chin, Christopher Granger, Frans Van De Werf, Fong Wang-Clow
  • Combination treatment with t-PA variant and low molecular weight heparin
    Publication number: 20060205662
    Abstract: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
    Type: Application
    Filed: May 15, 2006
    Publication date: September 14, 2006
    Inventors: Paul Armstrong, Hal Barron, Silvano Berioli, Frederique Bigonzi, Erich Bluhmki, Richard Chin, Christopher Granger, Frans De Werf, Fong Wang-Clow
  • Combination treatment with t-PA variant and low molecular weight heparin
    Patent number: 7084118
    Abstract: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: August 1, 2006
    Assignees: Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Aventis Pharma, S.A., Boehringer Ingelheim Pharma KG
    Inventors: Paul Armstrong, Hal Barron, Silvano Berioli, Frederique Bigonzi, Erich Bluhmki, Richard Chin, Christopher Granger, Frans Van De Werf, Fong Wang-Clow
  • Combination treatment with t-PA variant and low molecular weight heparin
    Publication number: 20040029798
    Abstract: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
    Type: Application
    Filed: February 21, 2003
    Publication date: February 12, 2004
    Inventors: Paul Armstrong, Hal Barron, Silvano Berioli, Frederique Bigonzi, Erich Bluhmki, Richard Chin, Christopher Granger, Frans Van De Werf, Fong Wang-Clow